Cargando…

A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreove...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yuting, Wei, Li, Kim, Seok Jin, Wang, Liang, He, Yingzhi, Zheng, Yanfang, Bertero, Luca, Pellerino, Alessia, Cassoni, Paola, Tamagnone, Luca, Theresa, Prochazka Katharina, Deutsch, Alexander, Zhan, Huien, Lai, Jing, Wang, Yao, You, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370855/
https://www.ncbi.nlm.nih.gov/pubmed/34422649
http://dx.doi.org/10.3389/fonc.2021.696147
_version_ 1783739519692963840
author Gao, Yuting
Wei, Li
Kim, Seok Jin
Wang, Liang
He, Yingzhi
Zheng, Yanfang
Bertero, Luca
Pellerino, Alessia
Cassoni, Paola
Tamagnone, Luca
Theresa, Prochazka Katharina
Deutsch, Alexander
Zhan, Huien
Lai, Jing
Wang, Yao
You, Hua
author_facet Gao, Yuting
Wei, Li
Kim, Seok Jin
Wang, Liang
He, Yingzhi
Zheng, Yanfang
Bertero, Luca
Pellerino, Alessia
Cassoni, Paola
Tamagnone, Luca
Theresa, Prochazka Katharina
Deutsch, Alexander
Zhan, Huien
Lai, Jing
Wang, Yao
You, Hua
author_sort Gao, Yuting
collection PubMed
description BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL. METHODS: We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort. RESULTS: By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system. CONCLUSIONS: In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.
format Online
Article
Text
id pubmed-8370855
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83708552021-08-19 A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups Gao, Yuting Wei, Li Kim, Seok Jin Wang, Liang He, Yingzhi Zheng, Yanfang Bertero, Luca Pellerino, Alessia Cassoni, Paola Tamagnone, Luca Theresa, Prochazka Katharina Deutsch, Alexander Zhan, Huien Lai, Jing Wang, Yao You, Hua Front Oncol Oncology BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL. METHODS: We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort. RESULTS: By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system. CONCLUSIONS: In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model. Frontiers Media S.A. 2021-08-03 /pmc/articles/PMC8370855/ /pubmed/34422649 http://dx.doi.org/10.3389/fonc.2021.696147 Text en Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gao, Yuting
Wei, Li
Kim, Seok Jin
Wang, Liang
He, Yingzhi
Zheng, Yanfang
Bertero, Luca
Pellerino, Alessia
Cassoni, Paola
Tamagnone, Luca
Theresa, Prochazka Katharina
Deutsch, Alexander
Zhan, Huien
Lai, Jing
Wang, Yao
You, Hua
A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_full A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_fullStr A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_full_unstemmed A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_short A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
title_sort novel prognostic marker for primary cns lymphoma: lactate dehydrogenase-to-lymphocyte ratio improves stratification of patients within the low and intermediate mskcc risk groups
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370855/
https://www.ncbi.nlm.nih.gov/pubmed/34422649
http://dx.doi.org/10.3389/fonc.2021.696147
work_keys_str_mv AT gaoyuting anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT weili anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT kimseokjin anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT wangliang anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT heyingzhi anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT zhengyanfang anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT berteroluca anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT pellerinoalessia anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT cassonipaola anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT tamagnoneluca anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT theresaprochazkakatharina anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT deutschalexander anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT zhanhuien anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT laijing anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT wangyao anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT youhua anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT gaoyuting novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT weili novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT kimseokjin novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT wangliang novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT heyingzhi novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT zhengyanfang novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT berteroluca novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT pellerinoalessia novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT cassonipaola novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT tamagnoneluca novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT theresaprochazkakatharina novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT deutschalexander novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT zhanhuien novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT laijing novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT wangyao novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups
AT youhua novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups